Relitect
About:
Relitect is developing a novel assay platform for the label free electrochemical detection of binding events.
Website: http://www.relitect.com/
Top Investors: IP Group, Scottish Enterprise
Description:
Relitect is developing a novel assay platform for the label free electrochemical detection of binding events. The company's proprietary technology can be applied for high sensitivity, multiplexed diagnostic and life science research products.
Total Funding Amount:
750000 GBP
Headquarters Location:
Glasgow, Glasgow City, United Kingdom
Founded Date:
2014-01-01
Founders:
Christoph Walti, Giles Davies
Number of Employees:
11-50
Last Funding Date:
2015-03-08
IPO Status:
Private
Industries:
© 2025 bioDAO.ai